论文部分内容阅读
将有着162年历史的全球制药行业的领军者重新转型为一家纯研发型药企,虽然冒险,但或许是一种十分明智的选择。5月20日,上海医药(02607.HK)在香港联交所挂牌交易。“亚洲最大”之外,挂牌另一个亮点是:此次,辉瑞中国投资5000万美元,成为上海医药基础投资者中的一员。在公众的印象中,有着162年历史的辉瑞,是全球制药行业的领军者。2010年,其销售收入达到678亿美元,甚至大于中国制药百强企业的当年总产值。但就是这样一家公司,似乎正有“放弃以规模取胜”的打算。
Re-transforming the leader of the 162-year-old global pharmaceutical industry into a purely R & D-based pharmaceutical company may be a smart choice, though risky. On May 20, Shanghai Pharmaceutical (02607.HK) was listed on the Hong Kong Stock Exchange. “Asia’s largest ”, listed another bright spot is: This time, Pfizer China invested 50 million US dollars, Shanghai Pharmaceutical to become a member of the basic investors. Pfizer, a 162-year-old publicist, is a global leader in the pharmaceutical industry. In 2010, its sales revenue reached 67.8 billion US dollars, even more than the top 100 Chinese pharmaceutical companies output value. But such a company, it seems, is “to give up the scale to win ” plan.